[CLSTR]
< Back to situation

[REVISION HISTORY]

Philip Morris earnings, forecast cut, IQOS & Zyn growth

Updated 4 times since CLSTR started tracking revisions of this situation.

What changed

2026-07-31 22:52 UTC → 2026-08-22 23:38 UTC · added removed

In early July 2026, Philip Morris International posted first‑quarter (PMI) reported first-quarter earnings of $1.96 per share on $10.15 billion revenue and later in revenue. Institutional activity during this period saw Ibex Wealth Advisors purchasing approximately 30,940 shares, while Summit Securities Group LLC significantly reduced its stake. By late July, PMI reported second‑quarter second-quarter revenue of $11.2 billion, with the smoke‑free segment rising a 10.4% year-on-year increase driven by a 11.7% to about rise in the smoke-free segment, which now accounts for roughly 42% of sales. Adjusted While adjusted EPS reached $2.20, but the full‑year company trimmed its full-year profit outlook was trimmed to $8.26‑$8.41 $8.26–$8.41 per share amid stronger competition in nicotine‑pouch products and share, citing adverse currency effects. The company accelerated effects and intensifying competition in nicotine-pouch products. To bolster its U.S. Zyn portfolio after following FDA approval authorization of new variants and, in late July, confirmed that variants, PMI doubled its investment in the Aurora, Colorado manufacturing campus will receive a to $1.2 billion investment through 2028—double the original commitment. 2028. The 780,000‑square‑foot, 148‑acre facility, which began full commercial production in July 2026, will supply Zyn pouches for domestic use and export to Asia, Latin America America, and the Caribbean, creating roughly 500 direct and 1,000 indirect jobs and an estimated $550 million in annual economic impact. IQOS continued to gain market share, achieving a 21.5% off‑take in global travel‑retail airports. Institutional activity included Clough Capital Partners acquiring about 50,000 Strategically, PMI shares. PMI’s CEO highlighted momentum from the first half is transitioning toward a goal of generating two-thirds of revenue from smoke-free products by 2030. This includes expanding the year IQOS platform and reaffirmed confidence in meeting annual targets, while noting industry‑wide shifts toward next‑generation nicotine products, appointing Bahar Demirci as reflected senior director of smoke-free products to oversee brand strategies in comparable the United Kingdom and Ireland. The company has also maintained a dividend growth reported by British American Tobacco. trajectory for seventeen consecutive years.

Versions

  1. 2026-08-22 23:38 UTC Philip Morris earnings, forecast cut, IQOS & Zyn growth
  2. 2026-07-31 22:52 UTC Philip Morris earnings, forecast cut, IQOS & Zyn growth
  3. 2026-07-28 11:29 UTC Philip Morris earnings, forecast cut, IQOS & Zyn growth
  4. 2026-07-28 10:11 UTC Philip Morris earnings, forecast cut, IQOS & Zyn growth
  5. 2026-07-27 12:34 UTC Philip Morris earnings, forecast cut, IQOS expansion

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.